Background and objectve: Hyper prolactinemia is a disorder which is presented in clinical forms of galatrrhea infertility, menstural disorder, hirsotism and PMS. Bromocriptin is agonist of dopamine and a drug for treatment of this disorder. Because of the necessity in continuous consumption of this drug (even for many years), the acceptance of the patients to the drug is important. In the present study the side-effects and acceptance level of patients to bromocriptin for the two forms of oral and vaginal use were studied.

  Methods: This study is a single-blinded clinical trial. Cases of study were patients referring Gynecology clinic with complaints of “Galactoria, Hirsotism, Menstural disorders and infertility.” The samples were 180 (two groups of 90 members each) and the length of study was two years. The samples were divided into two groups, (oral & vaginal). Before the start of the study, cases underwent, in terms of systemic and local complication, systemic and gynceologic examination to control systemic and local side effects. After health assurance of other systems, drugs were administered in two forms one group oral and the other group vaginal. The data was collected on the basis of questionnaire and analyzed by SPSS.

  Results: This study showed the side effects of Bromcriptin in oral-forms they were 100% and for vaginal-froms they were 43.2%. Most of the side effects in oral froms were nausea 38.9% and in vaginal from was vaginal itching (22.3%). Vertingo in oral forms was more than vaginal form (27.8% to 2.3%). Hypotension was seen in 11.2% of oral forms but not in vaginal form. About 51.2% of oral form group had more than two complications. In both groups the most complications were seem within the first ten days (37.8% and 66.7%). Severity of side effects in 31.2% of oral forms and 11% of vaginal forms were so tense that resulted to patients' discontinuation of the drug.

  Conclusion: There is a significant difference between severity, intensity and kind of complications in the forms of oral and vaginal use of Branocriptin and acceptance and duration of drug intake in vaginal forms is more than oral forms.